

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: True Leaf Medicine International Ltd. (the "Issuer").

Trading Symbol: MJ

Number of Outstanding Listed Securities: 71,505,802 common shares (plus 13,421,264 common shares reserved for issuance in the form of 7,780,028 warrants and 5,641,236 options) as at January 2, 2018.

Date: January 4, 2018

Report on Business

1. **Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.**

During the past month, the Issuer generally continued to market its pet products and to develop its pet product line.

During the past month, the Issuer followed up with potential investors in connection with its Regulation A+ offering, which was qualified by the Securities and Exchange Commission on November 21, 2017 (the "Offering"). The Offering enables underwriters to solicit orders from the general public in addition to traditional accredited investors and institutional investors. The Issuer is offering a maximum of 14,285,715 common shares at a price of \$0.70 CAD per share, with a minimum subscription amount of \$350 (500 shares) per investor. Boustead Securities, LLC is serving as lead underwriter for the Offering. In addition to traditional marketing methods used in public offerings, this offering is being marketed to online investors via invest.trueleaf.com. The Issuer is conducting a concurrent offering in Canada under the same terms as the Offering relying on the offering memorandum and accredited investor exemption.

On December 18, 2017, the Issuer retained Edison Advisors ("Edison"), a global strategic advisory firm, as the Issuer's investor relations advisor. Under the terms of the agreement the Issuer is required to pay Edison \$8,000 USD per month. The agreement is for a term of 12 month, and can be cancelled on 90 days written notice.

On December 22, 2017, the Issuer's wholly owned subsidiary True Leaf Medicine Inc. ("TLM") exercised its option to purchase a 40-acre parcel of land in Lumby, BC (the "Property") from a private British Columbia company. The seller is at arm's length to the Issuer (the "Optionor"). The closing date has been set for January 22, 2017, TLM paid an initial sum of \$100,000 on entering into the option agreement and is required to pay an additional \$3,200,000 plus GST on closing. TLM currently leases a portion of the Property from the Optionor and expects to use the Property, as well as the existing building thereon, in connection with its proposed medical

cannabis operations.

On December 29, 2017, the Issuer announced it had been assigned the the Legal Entity Identifier ("LEI") number 5299001MM2N2GXFEJP91. The European Union has adopted regulations that require use of the LEI as a barcode equivalent aimed at pinpointing systemic risks. The Issuer now meets the requirement for all companies listed on German stock exchanges (ie. Frankfurt Stock Exchange) to have a LEI number by January 3, 2018.

2. Provide a general overview and discussion of the activities of management.

Please see Item 1 above.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None, except in the ordinary course of business.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

On December 18, 2017, the Issuer announced that it has retained Edison Advisors ("**Edison**"), a global strategic advisory firm, as the Issuer's investor relations advisor. Under the terms of the agreement the Issuer is required to pay Edison \$8,000 USD per month. The agreement is for a term of 12 month, and can be cancelled on 90 days written notice.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any

valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None.

8. Describe the acquisition of new customers or loss of customers.

None, except in the ordinary course of business.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None, except in the ordinary course of business.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Please see Item 1 above.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds⁽¹⁾
Common Share	25,000	These shares were issued on December 5, 2017 upon the exercise of outstanding warrants at a price on \$0.45 per share	\$11,250 for general corporate purposes
Common Share	20,000	These shares were issued on December 5,	\$9,000 for general corporate purposes

		2017 upon the exercise of outstanding warrants at a price on \$0.45 per share	
Common Share	10,500	These shares were issued on December 5, 2017 upon the exercise of outstanding warrants at a price on \$0.45 per share	\$4,725 for general corporate purposes
Common Share	40,000	These shares were issued on December 5, 2017 upon the exercise of outstanding warrants at a price on \$0.45 per share	\$18,000 for general corporate purposes
Common Share	7,000	These shares were issued on December 21, 2017 upon the exercise of outstanding warrants at a price on \$0.45 per share	\$3,150 for general corporate purposes
Common Share	120,000	These shares were issued on December 21, 2017 upon the exercise of outstanding option at a price on \$0.395 per share	\$47,400 for general corporate purposes
Common Share	10,000	These shares were issued on December 21, 2017 upon the exercise of outstanding warrants at a price on \$0.45 per share	\$4,500 for general corporate purposes
Common Share	10,000	These shares were issued on December 21, 2017 upon the exercise of outstanding warrants at a price on \$0.45 per share	\$4,500 for general corporate purposes
Common Share	500,000	These shares were issued on December 21, 2017 upon the exercise of outstanding warrants at a price on \$0.15 per share	\$75,000 for general corporate purposes

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.

None.

16. Provide details of any changes in directors, officers or committee members.

None.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

None.

[Certificate on Next Page]

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated January 4, 2018.

Darcy Bomford
Name of Director or Senior Officer

"Darcy Bomford"
Signature

Chief Executive Officer
Official Capacity

Issuer Details Name of Issuer	For Month End	Date of Report YY/MM/DD
True Leaf Medicine International Ltd.	December 2017	18/01/04
Issuer Address		
100 Kalamalka Lake Road, Unit 32		
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.
Vernon, British Columbia V1T 9G1	N/A	778.475.5323
Contact Name	Contact Position	Contact Telephone No.
Darcy Bomford	President, CEO, and Director	778.475.5323
Contact Email Address	Web Site Address	
Darcy@trueleaf.com	www.trueleaf.com	